Arthneeti
Financial resultsMajor developmentFiled on BSE ·

Dr. Agarwal's Health Care approves H1 results; Amar Agarwal seeks Executive Chairman role

Dr Agarwals Health Care · Healthcare Services

Arthneeti Research DeskPublished 1 min read

Key highlights

  • Approved unaudited Standalone & Consolidated financial results for quarter and half year ended Sept 30, 2026, reviewed by S.R. Batliboi & Associates LLP
  • Scheme of Amalgamation between Dr. Agarwal's Eye Hospital Limited and Dr. Agarwal's Health Care Limited became effective Nov 1, 2026, with appointed date Apr 1, 2026
  • Dr. Amar Agarwal's appointment as Executive Chairman (Whole-Time Director) for three years from Nov 1, 2026 needs member approval via postal ballot; terms same as at Dr. Agarwal's Eye Hospital

Why it's rated major development: the year-on-year change is 56% (50% or more)

Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.

Original filing

Board Meeting Outcome for Consolidated And Standalone Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2026 And Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015

Read the filing on BSE (PDF) →

Companies guiding to strong growth

Ranked by management's own guidance on revenue and margins — not by us.

Waaree Energies Ltd

Electrical Equipment

Revenue growth 40%+Margin up 2%+

Sign up free to see all 6 →

See full rankings

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

More from Dr Agarwals Health Care

Other financial results filings this fortnight

All financial results filings →

Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.